Chemoprevention in postmenopausal women

Menopause

Volumn 15, Issue SUPPL. 4, 2008, Pages 810-815

  Rastogi, Priya ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Aromatase inhibitors; Breast cancer risk reduction; Chemoprevention; Raloxifene; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; RALOXIFENE; TAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGE; BREAST CANCER; CANCER RISK; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; FEMALE; FRACTURE; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UTERUS CANCER; VENOUS THROMBOEMBOLISM; BREAST TUMOR; RISK ASSESSMENT;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 58149354899     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318178863e     Document Type: Review

References (30)

1. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003;361:296-300.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
3. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652-1662.
5. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:98-101.
6. Powles T, Ashley S, Tidy A, Smith I, Dowsett M. Twenty-year followup of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283-290.
7. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-97.
8. Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomized women. Lancet 2002;359:1122-1124.
9. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-165.
10. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 2007;99:727-737.
11. IBIS Investigators. First results from the International Breast Cancer Intervention study (IBIS-I): a randomized prevention trial. Lancet2002;360:817-824.
12. Cuzick J, Forbes J, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancerV96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-282.
13. Olevsky OM, Martino SC. Randomized clinical trials of raloxifen: reducing the risk osteoporosis and breast cancer in postmenopausal women. Menopause 2008;15:790-796.
14. Vogel V, Costantino J, Wickerham D, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
15. Land S, Wickerham D, Costantino J, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006;295:2742-2751.
16. Cauley J, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65: 125-134.
17. Martino S, Cauley J, Barrett-Conner E, et al. Continuing Outcomes Relevant to Evista: a randomized trial of raloxifene in postmenopausal women with osteoporosis. J Natl Cancer Inst 2004;96: 1751-1761.
18. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst1999;91:1829-1846.
19. Hollingsworth AB, Singletary SE, Morrow M, et al. Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg 2004;187:349-362.
20. Vogel VG. Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer. Menopause 2008;15: 782-789.
21. Newman LA, Vogel VG. Breast cancer risk assessment and risk reduction. Surg Clin N Am 2007;87:307-316.
22. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137.
23. Thuerlimann B. Adjuvant hormonal therapy for breast cancer: an evolving process (archived web conference). Paper presented at: Primary Therapy of Early Breast Cancer 9th International Conference; January 26-29, 2005; St. Gallen, Switzerland. Available at: www.medscape.com/viewprogram/3800-pnt. Accessed March 3, 2005.
24. Jakesz R, on behalf of the ABCSG and the GABG. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,224 women enrolled in the ABCSG Trial 8 and the ARNO 95 trial. Paper presented at: 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX.
25. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer. N Engl J Med 2003;349:1793-1802.
26. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:1081-1092.
27. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
28. Cuzick J. Aromatase inhibitors in preventionVdata from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 2003;163:96-103.
29. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005;23:1636-1643.
30. Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol 2007;14:89-96.